Skip to Main Content

WASHINGTON  — Reality has a way of weighing down every politician who promises to address rising drug prices, and President Donald Trump may soon join their ranks.

That was the outlook of Ed Haislmaier, a senior fellow at the Heritage Foundation and former Pfizer policy director who advised Trump’s transition team. He spoke with STAT by phone recently.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!